NCT05879926 2026-03-03
OFSET
NRG Oncology
Phase 3 Recruiting
Clinical Trials
19 trialsNCT02767661 2026-02-27
MECCA
Sun Yat-sen University
Phase 3 Completed
NCT07400523 2026-02-10
Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting
NCT01160211 2025-03-07
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
Novartis
Phase 3 Completed
NCT06447623 2024-06-07
Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer
Fudan University
Phase 3 Recruiting
NCT03462251 2023-01-19
RIBBIT
iOMEDICO AG
Phase 3 Completed
NCT02914158 2023-01-17
ASPAIT
First Affiliated Hospital, Sun Yat-Sen University
Phase 3 Unknown
NCT02511639 2020-12-03
MAIN-A
Istituto Oncologico Veneto IRCCS
Phase 3 Completed
NCT00005970 2020-08-14
Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT01950182 2020-07-15
SYSUCC-002
Sun Yat-sen University
Phase 3 Completed
NCT02338310 2020-02-17
POETIC
Institute of Cancer Research, United Kingdom
Phase 3 Active not recruiting
NCT02995772 2019-06-19
Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients
Dharmais National Cancer Center Hospital
Phase 3 Completed
NCT02769104 2018-01-09
ACCN
Zhejiang Cancer Hospital
Phase 3 Unknown
NCT02394496 2016-06-15
OVER
Consorzio Oncotech
Phase 3 Unknown
NCT00044291 2015-07-31
Phase III Study of Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Completed
NCT00629278 2013-08-07
Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00097344 2007-08-23
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
Intarcia Therapeutics
Phase 3 Terminated